Rafael (“Rafa”) began his professional career in South San Francisco, California, where he joined Genentech’s Purification Process Development organization. He then moved to Amgen Thousand Oaks where he continued to work on the development and implementation of protein purification processes to supply early-stage clinical trials. After developing expertise in the PD laboratory, Rafa joined Amgen’s Process Engineering organization where he supported the technology transfer, scale-up, and commercialization of therapeutic protein manufacturing processes. He then joined the supplier side of the business and was employed at Repligen as a Field Applications Scientist where he provided pre- and post-sale technical support for downstream TFF operations, including hollow fiber and flat sheet TFF filters and TFF systems. Rafa is now a Field Applications Specialist at Ecolab Life Sciences, supporting customers with the use of Praesto resins for downstream bioprocess applications. Rafa received his Bachelor of Science in Chemical Engineering from UC Berkeley.
As global healthcare systems push for affordability, reducing the cost of monoclonal antibody (mAb) manufacturing has become a top priority. Chromatographic capture and polishing steps remain among the most expensive operations in downstream processing, especially in legacy workflows. Moving to modern resins can deliver significant savings and productivity gains, but the transition must preserve product quality, regulatory compliance, and compatibility with existing processes.
This presentation examines the challenges and opportunities in replacing traditional Protein A resins with next-generation alternatives. We will explore why cost pressures and biosimilar development are driving change, outline critical considerations for resin adoption, and share strategies to minimize complexity during implementation. Finally, we will highlight how Ecolab’s Praesto AP+ Resin Platform was engineered to simplify this transition, offering robust performance, regulatory assurance, and cost efficiency for commercial and biosimilar manufacturing. Attendees will gain practical insights into planning and executing resin transitions that deliver measurable benefits without disrupting established workflows.